Patheon Inc. Restructure Complete; New Company, DPx Expects $2 Billion In Annual Sales

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Restructuring of the former Patheon Pharmaceuticals has been completed, and the pharmaceutical services company is now a business unit of DPx Holdings B.V. (DPx).

DPx is privately owned by JLL Partners and Royal DSM and launched as a global contract development and manufacturing organization (CDMO) for the pharmaceutical and related industries. DPx is the result of a $2.65 billion transaction between JLL Partners, a middle-market private equity firm, and Royal DSM, a Netherlands-based life sciences conglomerate.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC